GeneChem

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative therapies targeting metabolic and fibrotic disorders. The company specializes in peripherally-restricted CB1 receptor inverse agonists, which aim to offer new treatment options for conditions such as Prader-Willi syndrome, diabetes, and related metabolic disorders. Inversago Pharma's research includes addressing complications associated with diabetic kidney disease, non-alcoholic steatohepatitis, and various fibrotic diseases, including interstitial lung disease. Founded in 2015, the company is dedicated to enhancing patient outcomes through its pioneering approach to CB1 blockade.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative therapies targeting metabolic and fibrotic disorders. The company specializes in peripherally-restricted CB1 receptor inverse agonists, which aim to offer new treatment options for conditions such as Prader-Willi syndrome, diabetes, and related metabolic disorders. Inversago Pharma's research includes addressing complications associated with diabetic kidney disease, non-alcoholic steatohepatitis, and various fibrotic diseases, including interstitial lung disease. Founded in 2015, the company is dedicated to enhancing patient outcomes through its pioneering approach to CB1 blockade.

Liminal BioSciences Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative treatments for patients with unmet medical needs, particularly focusing on rare and orphan diseases. The company operates through two main segments: Small Molecule Therapeutics and Plasma Derived Therapeutics. Its lead product candidate, fezagepras, targets idiopathic pulmonary fibrosis, respiratory diseases, and Alström Syndrome. In the Plasma Derived Therapeutics segment, Liminal BioSciences offers a Plasma Protein Purification System for extracting and purifying therapeutic proteins from human plasma and is developing Ryplazim for congenital plasminogen deficiency. Founded in 1992 and headquartered in Laval, Quebec, the company has a presence in Canada, the United Kingdom, and the United States. It was previously known as Prometic Life Sciences Inc. before rebranding in October 2019.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative therapies targeting metabolic and fibrotic disorders. The company specializes in peripherally-restricted CB1 receptor inverse agonists, which aim to offer new treatment options for conditions such as Prader-Willi syndrome, diabetes, and related metabolic disorders. Inversago Pharma's research includes addressing complications associated with diabetic kidney disease, non-alcoholic steatohepatitis, and various fibrotic diseases, including interstitial lung disease. Founded in 2015, the company is dedicated to enhancing patient outcomes through its pioneering approach to CB1 blockade.

SemaThera Inc. is a biotechnology company based in Montreal, Canada, focused on developing innovative therapies targeting the SEMA 3A protein for the treatment of various ocular diseases, particularly diabetic macular edema and wet age-related macular degeneration. Established in 2016 as a spin-off from the AmorChem Venture Fund 1, SemaThera's technology originates from the research of Dr. Mike Sapieha at Hôpital Maisonneuve-Rosemont. The company's efforts aim to provide effective protein inhibitors that can address not only ocular conditions but also have potential applications in treating cancer and neurodegenerative diseases.